Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM2 | O94759 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | ENTPD1 | P49961 | 3/20 | 0.51 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | DTYMK | P23919 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042426 | 1.00 | TRPM2 (0.56) | TRPM2POLBENTPD1ENPP1P2RY1 | |
| SCHEMBL1881041 | 0.93 | POLB (0.52) | TRPM2POLBENTPD1ENPP1P2RY1 | |
| SCHEMBL4209829 | 0.86 | ENTPD1 (0.66) | TRPM2ENTPD1 | |
| SCHEMBL4206199 | 0.85 | ENTPD1 (0.67) | TRPM2ENTPD1 | |
| SCHEMBL7644549 | 0.83 | TRPM2 (0.65) | TRPM2POLBENTPD1ENPP1P2RY1 | |
| SCHEMBL8917329 | 0.83 | ADORA3 (0.55) | — | |
| SCHEMBL7599209 | 0.83 | ADORA3 (0.55) | — | |
| SCHEMBL30134675 | 0.82 | TRPM2 (0.64) | TRPM2POLBENTPD1ENPP1P2RY1 | |
| SCHEMBL12932270 | 0.82 | TRPM2 (0.64) | TRPM2POLBENTPD1ENPP1P2RY1 | |
| SCHEMBL1063721 | 0.82 | TRPM2 (0.64) | TRPM2POLBENTPD1ENPP1P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952587-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220064741-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2022-03-03 | — | — | US | disclosed |
| US-20180334729-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2018-11-22 | — | — | US | disclosed |
| US-9920386-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160208344-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2016-07-21 | — | — | US | disclosed |
| EP-2952587-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2171088-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20130172197-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8349565-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8324360-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110251079-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7939259-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2171088-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2009-02-05 | — | — | US | disclosed |
| WO-2008157696-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | TRPM2 4434/4885POLB 137/4885ENTPD1 441/4885 |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | TRPM2 4434/4885POLB 137/4885ENTPD1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.